|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | A61K 31/337 | |
| A61K 31/7068 | |||
| A61K 31/35 | |||
| A61K 31/357 | |||
| A61K 31/282 | |||
| A61K 31/427 | |||
| A61K 31/555 | |||
| A61K 31/704 | |||
| A61K 33/24 | |||
| A61K 45/06 | |||
| A61P 35/00 | |||
| A61P 15/08 | |||
| C12Q 1/68 | |||
| A61K 9/00 |
| (11) | Number of the document | 3148526 |
| (13) | Kind of document | T |
| (96) | European patent application number | 15799560.6 |
| Date of filing the European patent application | 2015-05-27 | |
| (97) | Date of publication of the European application | 2017-04-05 |
| (45) | Date of publication and mention of the grant of the patent | 2021-01-06 |
| (46) | Date of publication of the claims translation |
| (86) | Number | PCT/US2015/032684 |
| Date | 2015-05-27 |
| (87) | Number | WO 2015/183961 |
| Date | 2015-12-03 |
| (30) | Number | Date | Country code |
| 201462003937 P | 2014-05-28 | US |
| (72) |
LITTLEFIELD, Bruce A., US
ASANO, Makoto, JP
MATSUI, Junji, JP
OLIVO, Martin, US
OZAWA, Yoichi, JP
YU, Yanke, US
|
| (73) |
Eisai R&D Management Co., Ltd.,
6-10 Koishikawa 4-chome, Tokyo 112-8088,
JP
|
| (54) | USE OF ERIBULIN IN THE TREATMENT OF CANCER |
| USE OF ERIBULIN IN THE TREATMENT OF CANCER |